Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64300535 in Chronic Hepatitis B
NCT03463369Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing JNJ-64300535 + NA with Placebo + NA (2 arms). Primary endpoints: Number of Participants with Adverse Events (AEs) by Severity and Relationship to Study Treatment and Dose Level, Number of Participants With Laboratory Abnormalities and 4 more. Started Apr 2018; status: completed.
02
Drugs
JNJ-64300535
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03463369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463369.